These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

367 related items for PubMed ID: 23389551

  • 1. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.
    Vasconcelos H, Marques I, Santos AR, Melo P, Pires I, Figueira J, de Abreu JF, Cachulo ML, Silva R.
    Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1697-705. PubMed ID: 23389551
    [Abstract] [Full Text] [Related]

  • 2. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V, Vysloužilová D, Uher M.
    Semin Ophthalmol; 2018 Jul; 33(5):690-699. PubMed ID: 29252091
    [Abstract] [Full Text] [Related]

  • 3. Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.
    Shinojima A, Kawamura A, Mori R, Fujita K, Yuzawa M.
    Retina; 2011 Oct; 31(9):1912-20. PubMed ID: 21952105
    [Abstract] [Full Text] [Related]

  • 4. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K, Shinoda K, Imamura Y, Matsumoto CS, Mizutani Y, Mizota A, Yuzawa M.
    Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
    [Abstract] [Full Text] [Related]

  • 5. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Gulkas S, Sahin O.
    Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
    Senturk F, Karacorlu M, Ozdemir H, Karacorlu SA, Uysal O.
    Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Reibaldi M, Boscia F, Avitabile T, Uva MG, Russo A, Zagari M, Occhipinti F, Russo V, Reibaldi A, Longo A.
    Am J Ophthalmol; 2011 Jun; 151(6):953-960.e2. PubMed ID: 21457929
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy.
    Iacono P, Tedeschi M, Boccassini B, Chiaravalloti A, Varano M, Parravano M.
    Retina; 2019 May; 39(5):980-987. PubMed ID: 29346241
    [Abstract] [Full Text] [Related]

  • 12. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.
    Fujita K, Yuzawa M, Mori R.
    Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236
    [Abstract] [Full Text] [Related]

  • 13. The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.
    Hagen S, Ansari-Shahrezaei S, Smretschnig E, Glittenberg C, Krebs I, Graf A, Binder S.
    Graefes Arch Clin Exp Ophthalmol; 2013 Apr; 251(4):1081-9. PubMed ID: 22926253
    [Abstract] [Full Text] [Related]

  • 14. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy.
    Pryds A, Larsen M.
    Acta Ophthalmol; 2012 Dec; 90(8):738-43. PubMed ID: 21586096
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.
    Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M.
    Int Ophthalmol; 2017 Jun; 37(3):483-489. PubMed ID: 27392913
    [Abstract] [Full Text] [Related]

  • 16. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
    Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF.
    Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
    [Abstract] [Full Text] [Related]

  • 17. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.
    van Rijssen TJ, Mohabati D, Dijkman G, Theelen T, de Jong EK, van Dijk EHC, Boon CJF.
    PLoS One; 2018 Sep; 13(8):e0202549. PubMed ID: 30142176
    [Abstract] [Full Text] [Related]

  • 18. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
    Arevalo JF, Espinoza JV.
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M.
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.